Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL
Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.